Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Urothelial Carcinoma (UC)
Clinical trial register · China

Urothelial Carcinoma (UC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Shanghai 3 Tianjin 2 Wuxi 2 Beijing 2 Fuzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai3 Tianjin2 Wuxi2 Beijing2 Fuzhou1
All 13 locations
Target enrolment
to

Urothelial Carcinoma (UC) trials in China

12 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
42
Guangzhou
2026-09
Recruiting
Yunnan Cancer Hospital
Phase 2
30
Kunming
2026-08-01
Recruiting
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
NCT07518043Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC)
DrugOpdivo
Shanghai Henlius Biotech
Phase 1
174
Fuzhou, Hangzhou, Luoyang, Tianjin, Wenzhou, Wuhan, Xi'an
2026-07-15
Not yet open
Akeso
Phase 2
132
Shanghai
2026-06-22
Recruiting
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NCT07557225Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
Peking University First Hospital
Not applicable
200
Beijing
2026-04-27
Recruiting
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1
10
Shanghai
2026-04-13
Recruiting
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
NCT07888374Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer
Ruijin Hospital
Observational
477
Shanghai
2026-04-05
By invitation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
4,000
Beijing
2026-03-02
Recruiting
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
NCT07441499Urothelial Carcinoma (UC), Bladder (Urothelial, Transitional Cell) Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
300
Tianjin
2026-03
By invitation
Affiliated Hospital of Jiangnan University
Early Phase 1
20
Wuxi
2025-07-01
By invitation
Affiliated Hospital of Jiangnan University
Early Phase 1
10
Wuxi
2025-07-01
Recruiting
Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis
NCT07614594Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, UTUC, Bladder Cancer (BC)
Henan Provincial People's Hospital
Observational
800
Zhengzhou
2019-10-08
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/condition/urothelial-carcinoma-uc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies listing the condition Urothelial Carcinoma (UC).

How many Urothelial Carcinoma (UC) trials are recruiting in China?

7 of the 12 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 0 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Urothelial Carcinoma (UC)), 12 studies
PhaseStudiesRecruitingShare
Observational4333.3%
Early Phase 13125%
Phase 23125%
Not applicable118.3%
Phase 1118.3%

Most active sponsors

Lead sponsors with the most studies (Urothelial Carcinoma (UC))
Lead sponsorStudiesRecruiting
Affiliated Hospital of Jiangnan University20
Akeso10
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Henan Provincial People's Hospital11
Peking University First Hospital11
Ruijin Hospital11
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine11
Shanghai Henlius Biotech11
Sichuan Baili Pharmaceutical Co., Ltd.10
Tianjin Medical University Second Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.